These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9519278)

  • 21. The AMPA receptor antagonist NBQX exerts antidystonic effects in an animal model of idiopathic dystonia.
    Richter A; Löscher W; Löschmann PA
    Eur J Pharmacol; 1993 Feb; 231(2):287-91. PubMed ID: 8384114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline.
    Turski L; Jacobsen P; Honoré T; Stephens DN
    J Pharmacol Exp Ther; 1992 Feb; 260(2):742-7. PubMed ID: 1371159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AMPA receptor competitive antagonism reduces halothane MAC in rats.
    McFarlane C; Warner DS; Todd MM; Nordholm L
    Anesthesiology; 1992 Dec; 77(6):1165-70. PubMed ID: 1334638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased basic fibroblast growth factor mRNA following contusive spinal cord injury.
    Follesa P; Wrathall JR; Mocchetti I
    Brain Res Mol Brain Res; 1994 Mar; 22(1-4):1-8. PubMed ID: 8015371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. It is AMPA receptor, not kainate receptor, that contributes to the NBQX-induced antinociception in the spinal cord of rats.
    Kong LL; Yu LC
    Brain Res; 2006 Jul; 1100(1):73-7. PubMed ID: 16777075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AMPA receptors and motivation for drug: effect of the selective antagonist NBQX on behavioural sensitization and on self-administration in mice.
    Jackson A; Mead AN; Rocha BA; Stephens DN
    Behav Pharmacol; 1998 Sep; 9(5-6):457-67. PubMed ID: 9832931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The AMPA antagonist NBQX protects thalamic reticular neurons from degeneration following cardiac arrest in rats.
    Ross DT; Brasko J; Patrikios P
    Brain Res; 1995 Jun; 683(1):117-28. PubMed ID: 7552336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Superoxide dismutase activity and the effects of NBQX and CPP on lipid peroxidation in experimental spinal cord injury.
    Görgülü A; Kiriş T; Unal F; Turkoğlu U; Küçük M; Cobanoğlu S
    Res Exp Med (Berl); 2000 Apr; 199(5):285-93. PubMed ID: 10815757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischaemia model.
    Gill R; Nordholm L; Lodge D
    Brain Res; 1992 May; 580(1-2):35-43. PubMed ID: 1504814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excitotoxic effects of non-NMDA receptor agonists in organotypic corticostriatal slice cultures.
    Kristensen BW; Noraberg J; Jakobsen B; Gramsbergen JB; Ebert B; Zimmer J
    Brain Res; 1999 Sep; 841(1-2):143-59. PubMed ID: 10546997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The mechanism by which NBQX enhances NMDA currents in retinal ganglion cells.
    Yu W; Miller RF
    Brain Res; 1996 Feb; 709(2):184-96. PubMed ID: 8833754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CNQX but not NBQX prevents expression of amphetamine-induced place preference conditioning: a role for the glycine site of the NMDA receptor, but not AMPA receptors.
    Mead AN; Stephens DN
    J Pharmacol Exp Ther; 1999 Jul; 290(1):9-15. PubMed ID: 10381753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NBQX, an improved non-NMDA antagonist studied in retinal ganglion cells.
    Yu W; Miller RF
    Brain Res; 1995 Sep; 692(1-2):190-4. PubMed ID: 8548303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the AMPA receptor antagonist NBQX on outcome of newborn pigs after asphyxic cardiac arrest.
    Brambrink AM; Martin LJ; Hanley DF; Becker KJ; Koehler RC; Traystman RJ
    J Cereb Blood Flow Metab; 1999 Aug; 19(8):927-38. PubMed ID: 10458600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuronal damage induced by beta-N-oxalylamino-L-alanine, in the rat hippocampus, can be prevented by a non-NMDA antagonist, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline.
    Willis CL; Meldrum BS; Nunn PB; Anderton BH; Leigh PN
    Brain Res; 1993 Nov; 627(1):55-62. PubMed ID: 7507397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys.
    Klockgether T; Turski L; Honoré T; Zhang ZM; Gash DM; Kurlan R; Greenamyre JT
    Ann Neurol; 1991 Nov; 30(5):717-23. PubMed ID: 1662477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticonvulsant action of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline in immature rats: comparison with the effects on motor performance.
    Mares P; Mikulecká A; Pometlová M
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1120-6. PubMed ID: 9190844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The network-selective actions of quinoxalines on the neurocircuitry operations of the rabbit retina.
    Cohen ED; Miller RF
    Brain Res; 1999 Jun; 831(1-2):206-28. PubMed ID: 10412000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of NADPH oxidase activation in oligodendrocytes reduces cytotoxicity following trauma.
    Johnstone JT; Morton PD; Jayakumar AR; Johnstone AL; Gao H; Bracchi-Ricard V; Pearse DD; Norenberg MD; Bethea JR
    PLoS One; 2013; 8(11):e80975. PubMed ID: 24260524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.